Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$66.66
-$0.34(-0.44%)
At close: 4:00 PM EST
$66.66
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)634.60K
Market Cap
$3.12B
Enterprise Value$4.14B
Total Cash (Recent Filing)$296.43M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)19.4
Beta0.56
Next Earnings
Feb 05, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding46,809,673
10 Day Avg. Volume864,515
30 Day Avg. Volume634,604
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit5.31
Enterprise Value/Ebitda11.04
Forecast
1Y Price Target
$88.86Price Target Upside33.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings And Guidance MomentumQuarterly beats and margin expansion, coupled with raised full-year guidance, support a more positive earnings outlook and enhance credibility with investors.
Plasma Demand RecoveryRebounding plasma collections could drive stronger revenue and improve company margins, with analysts noting plasma strength was not fully assumed in guidance.
Product Portfolio ExpansionAcquisition of Vivasure brings a bioabsorbable large-bore vascular closure device into the portfolio, filling a prior product gap and enabling better leverage of existing commercial channels.
Bears Say
Competitive Pressure In Vascular ClosureRising competition from established device makers and new venous closure entrants could pressure market share and compress margins in the vascular closure market.
Procedure Migration And Demand RiskShifts in procedure technology and migration of some heart procedures to outpatient settings could reduce demand for vascular closure devices and weaken interventional revenues.
Regulatory RiskLack of U.S. approval for the PerQseal device poses a key commercialization hurdle that could delay access to the majority of the large-bore market.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $3.12B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Feb 05, 2026 which is in 5 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Nov 06, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.16.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.25.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 46,809,673 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.27 in its last earnings report, beating expectations of $1.11. Following the earnings report the stock price went up 32.315%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.86 (33.30% Upside)
$88.86 (33.30% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 512.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.41%
12-Months-Change
Fundamentals
Return on Equity
19.47%
Trailing 12-Months
Asset Growth
-3.29%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in organic revenue, adjusted EPS, and gross margin expansion. Plasma and Blood Management Technologies showed robust performance, reinforcing strong cash generation and increased free cash flow guidance. However, overall revenue showed a decline due to portfolio transitions, and Interventional Technologies faced challenges. Despite these lowlights, the call maintained a positive outlook on future growth and profitability.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$88.86
▲(33.30% Upside)
Technical Analysis
Ownership Overview
1.38% Insiders
37.07% Mutual Funds
1.94% Other Institutional Investors
34.05% Public Companies and
Individual Investors